Palisade Capital Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Palisade Capital Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,233	Closed	-$40K	–	408
2022 Q3	$40K	Buy	22,233 +665	+3%	+$1.93K	﹤0.01%	405
2022 Q2	$122K	Hold	21,568	–	–	﹤0.01%	417
2022 Q1	$260K	Buy	21,568 +437	+2%	+$4.73K	0.01%	402
2021 Q4	$218K	Hold	21,131	–	–	﹤0.01%	415
2021 Q3	$685K	Hold	21,131	–	–	0.01%	345
2021 Q2	$905K	Hold	21,131	–	–	0.02%	334
2021 Q1	$1.04M	Hold	21,131	–	–	0.02%	311
2020 Q4	$742K	Hold	21,131	–	–	0.02%	319
2020 Q3	$859K	Hold	21,131	–	–	0.03%	316
2020 Q2	$951K	Hold	21,131	–	–	0.03%	306
2020 Q1	$1.13M	Buy	+21,131	New	+$1.65M	0.04%	314

Other funds holding FRTX

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Palisade Capital Management's FRTX Position: Q4 2022 in Review

Palisade Capital Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2022, closing a stake of 22,233 shares — an estimated $40K sold.

Palisade Capital Management first reported a position in FRTX in Q1 2020 and held it in 11 quarters. The position peaked at $1.13M in Q1 2020. 16 funds tracked by Wall St. Rank hold FRTX as of Q4 2022.

Palisade Capital Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Palisade Capital Management sold 22,233 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $40K.
Palisade Capital Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Palisade Capital Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.13M in Q1 2020.
16 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Palisade Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.